TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26449355

Group type: EXPERIMENTAL
Intervention: No mild cognitive impairment (MCI)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 319
Study: 26449490

Group type: EXPERIMENTAL
Intervention: Exacerbation history in the year before baseline
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Statistical regression equations
Number of subjects: 2164
Study: 26449993

Group type: EXPERIMENTAL
Intervention: STRATIFY decision tool
Number of subjects: 1033
Study: 26450421

Group type: EXPERIMENTAL
Intervention: Standard-dose BCG SSI
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Standard-dose BCG TICE
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-dose BCG SSI
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-dose BCG TICE
Number of subjects: 4
Study: 26450424

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia in controlled diabetes mellitus (HbA1c < 7 %)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia in uncontrolled diabetes mellitus (HbA1c > 7 %)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 26451031

Group type: EXPERIMENTAL
Intervention: Quantitative location model for ICH engagement
Number of subjects: 111
Study: 26451310

Group type: EXPERIMENTAL
Intervention: Autologous or donor-derived T cells expressing CD19 chimeric antigen receptors (CARs) with 4-1BB and CD3ζ moiety
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: No conditioning chemotherapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Donor-derived anti-CD19 CART cells
Number of subjects: 9
Study: 26452027

Group type: EXPERIMENTAL
Intervention: cfDNA sequencing using a 54-gene panel
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: cfDNA analysis during cetuximab-based treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: cfDNA analysis during cetuximab/irinotecan chemotherapy
Number of subjects: 75
Study: 26452346

Group type: EXPERIMENTAL
Intervention: GEP score variability (standard deviation of four GEP scores collected ≥315 days post-transplantation)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: GEP score variability
Number of subjects: 737
Study: 26452397

Group type: EXPERIMENTAL
Intervention: Second dose of herpes zoster vaccine (ZV) administered to participants aged ≥ 70 years.
Number of subjects: 200

Group type: COMPARATOR
Intervention: First dose of herpes zoster vaccine (ZV) administered to age-matched groups (100 participants aged 50-59 years, 100 aged 60-69 years, and 200 aged ≥ 70 years).
Number of subjects: 200
Study: 26452405

Group type: EXPERIMENTAL
Intervention: 14-day tailored therapy based on H. pylori culture and MIC test
Number of subjects: 219

Group type: COMPARATOR
Intervention: 14-day EBMT therapy
Number of subjects: 219

Group type: COMPARATOR
Intervention: 14-day MEA therapy
Number of subjects: 219
Study: 26452447

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-daily
Number of subjects: 958

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 958
Study: 26452561

Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB) monitored using acceleromyography, rNMB defined as a train-of-four (TOF) ratio <0.9
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: NMB reversed with neostigmine in 78% of patients
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Age <45 years
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Use of one neuromuscular blocking agent (NMBA)
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Time from neostigmine administration to endotracheal extubation ≥10 min
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Time from last NMBA administration to endotracheal extubation ≥60 min
Number of subjects: 1571
Study: 26453446

Group type: EXPERIMENTAL
Intervention: 1 Hz deep rTMS (1200 pulses) over the mPFC, followed by nine additional sessions of daily rTMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (aged-matched healthy controls)
Number of subjects: 20
Study: 26453479

Group type: EXPERIMENTAL
Intervention: Philips fluid accumulation vest (FAV) used for daily monitoring of transthoracic bioimpedance for 45 days post-discharge.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Philips fluid accumulation vest (FAV) monitoring.
Number of subjects: 180
Study: 26453592

Group type: EXPERIMENTAL
Intervention: STOPP/START criteria applied to health administrative data (HAD)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Beers criteria applied to health administrative data (HAD)
Number of subjects: 275
Study: 26453687

Group type: EXPERIMENTAL
Intervention: Sapien 3 THV
Number of subjects: 598

Group type: COMPARATOR
Intervention: Sapien XT THV
Number of subjects: 598
Study: 26453688

Group type: EXPERIMENTAL
Intervention: ST elevation or presumably new left bundle branch block
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Other ECG signs indicating myocardial ischemia
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: No ECG signs indicating myocardial ischemia
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Initial ECG findings
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Initial nonshockable rhythms
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Six-months survival with good neurological outcome
Number of subjects: 210
Study: 26453983

Group type: EXPERIMENTAL
Intervention: Progesterone on hCG day (mean ± SD: 1.13 ± 0.69 ng/mL) among agonist-treated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone on hCG day (mean ± SD: 1.11 ± 0.58 ng/mL) among recombinant FSH stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancy rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: P-hCG value
Number of subjects: 0
Study: 26454362

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay, concentrations less than 5 ng/L
Number of subjects: 6304

Group type: COMPARATOR
Intervention: Troponin concentration of 5 ng/L or more
Number of subjects: 6304
Study: 26454612

Group type: EXPERIMENTAL
Intervention: Dose-Dense Paclitaxel, Trastuzumab, and Lapatinib (PTL)
Number of subjects: 20
Study: 26454620

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (30 mg/m² on days 1 and 8 every 21 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Subsequent platinum-based chemotherapy (58% of patients)
Number of subjects: 31
Study: 26455862

Group type: EXPERIMENTAL
Intervention: OSNA (One step nucleic acid amplification) using CK19 mRNA concentration
Number of subjects: 55

Group type: COMPARATOR
Intervention: Histopathological analysis
Number of subjects: 55
Study: 26455870

Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemic episodes
Number of subjects: 5783

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemic episodes
Number of subjects: 5783

Group type: EXPERIMENTAL
Intervention: Any hypoglycaemic episode
Number of subjects: 5783

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 5783
Study: 26455892

Group type: EXPERIMENTAL
Intervention: Toddlers of GG mothers at the FADS2 rs174575 SNP
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Toddler methylation status
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Maternal methylation status
Number of subjects: 71
Study: 26456229

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy followed by endometrial biopsy for diagnosis of chronic endometritis (CE).
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy for diagnosis of CE.
Number of subjects: 99
Study: 26456677

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Number of subjects: 14
Study: 26457029

Group type: EXPERIMENTAL
Intervention: Third Eye Panoramic cap
Number of subjects: 33
Study: 26457065

Group type: EXPERIMENTAL
Intervention: Natural micronized progesterone vaginal tablet (FE 999913) administered twice daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study: 26457225

Group type: EXPERIMENTAL
Intervention: Generic drugs perception assessment
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Economic gain perception
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Pharmacovigilance mandates perception
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Comparison of scores by location and specialty
Number of subjects: 908
Study: 26457568

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g daily for 8 weeks)
Number of subjects: 14
Study: 26458184

Group type: EXPERIMENTAL
Intervention: DSM symptoms (e.g., sad mood)
Number of subjects: 3463

Group type: EXPERIMENTAL
Intervention: Non-DSM symptoms (e.g., anxiety)
Number of subjects: 3463

Group type: EXPERIMENTAL
Intervention: Network perspective
Number of subjects: 3463

Group type: EXPERIMENTAL
Intervention: Central symptoms research
Number of subjects: 3463
Study: 26458411

Group type: EXPERIMENTAL
Intervention: PPI use at the time of coronary intervention
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Discharge PPI use
Number of subjects: 8582
Study: 26458788

Group type: EXPERIMENTAL
Intervention: Manchester Triage System (MTS) implemented by triage nurses upon arrival in the ED.
Number of subjects: 2407
Study: 26458804

Group type: EXPERIMENTAL
Intervention: 10 μg DEN1-80E with 1.25 mg of elemental aluminum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 μg DEN1-80E with 1.25 mg of elemental aluminum
Number of subjects: 0
Study: 26458809

Group type: EXPERIMENTAL
Intervention: Public health nurse-delivered, publicly funded rotavirus vaccination program
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Physician-delivered program
Number of subjects: 722

Group type: COMPARATOR
Intervention: Control group (no vaccination program)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Public health-delivered vaccination program
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Universal rotavirus vaccination program
Number of subjects: 722
Study: 26459220

Group type: EXPERIMENTAL
Intervention: (11)C Pittsburgh compound B (PIB) PET scan to quantify global amyloid deposition
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hierarchical multiple linear regression analysis controlling for age, education, and ApoE ε4 status
Number of subjects: 22
Study: 26459321

Group type: EXPERIMENTAL
Intervention: Food responsiveness at 3 months
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Slowness in eating and satiety responsiveness at 3 months
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Appetitive traits at 12 months
Number of subjects: 210
Study: 26459405

Group type: EXPERIMENTAL
Intervention: Routine and novel cardiovascular, inflammatory and renal biomarkers assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up through telephone calls and questionnaires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global cardiovascular assessment through clinical exam, instrumental tests (electrocardiogram, echocardiogram), and biological parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological collection on plasma and urine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk stratification of ICU survivors
Number of subjects: 0
Study: 26459812

Group type: EXPERIMENTAL
Intervention: Bevacizumab (VEGF blockage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilengitide (Integrin inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib or Cediranib (VEGF receptor inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imatinib or Dasatinib (PDGFR inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzastaurin (Protein kinase C inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus, Everolimus, or Temsirolimus (mTOR inhibition)
Number of subjects: 0
Study: 26459932

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention and renal angiography
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Multivariate models
Number of subjects: 181
Study: 26459996

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) formula
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Barrett True-K formula (True-K)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wang-Koch-Maloney (WKM) formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Shammas formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Haigis-L formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Average of the five formulas
Number of subjects: 80
Study: 26460303

Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg orally twice a day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 21
Study: 26462280

Group type: EXPERIMENTAL
Intervention: Low-residue breakfast (LRB)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Clear fluids alone (CFD)
Number of subjects: 214
Study: 26462968

Group type: EXPERIMENTAL
Intervention: Strongest Families FASD intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (static resource Web page)
Number of subjects: 200
Study: 26464110

Group type: EXPERIMENTAL
Intervention: Peace of Mind Program (PMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (self as control)
Number of subjects: 0
Study: 26464393

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: First-line NIV for ARF
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Pre-ICU NIV
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Post-extubation NIV
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: First-line NIV in acute-on-chronic RF
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: First-line NIV in cardiogenic pulmonary edema
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: First-line NIV in de novo ARF
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: NIV success rate
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: NIV failure in de novo ARF
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 4132
Study: 26464429

Group type: EXPERIMENTAL
Intervention: Generic outcome adjudication module
Number of subjects: 7336

Group type: COMPARATOR
Intervention: Three-step adjudication procedure
Number of subjects: 7336

Group type: COMPARATOR
Intervention: Six-step adjudication procedure
Number of subjects: 7336
Study: 26464715

Group type: EXPERIMENTAL
Intervention: MAGE-A3-positive tumors
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PRAME-positive tumors
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: At least one antigen positive
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Assessment of tumor antigen mRNA expression
Number of subjects: 156
Study: 26464803

Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 54
Study: 26465217

Group type: EXPERIMENTAL
Intervention: Higher child-reported maternal warmth in early adolescence
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher child-reported maternal warmth in late adolescence
Number of subjects: 240

Group type: COMPARATOR
Intervention: Mother-reported warmth in early adolescence
Number of subjects: 240

Group type: COMPARATOR
Intervention: Mother-reported warmth in late adolescence
Number of subjects: 240
Study: 26465376

Group type: EXPERIMENTAL
Intervention: Postal questionnaires
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Telephone consultation
Number of subjects: 2566

Group type: COMPARATOR
Intervention: E-mail consultation
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Age-related preference for e-mail
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Gender-related preference
Number of subjects: 2566
Study: 26465392

Group type: EXPERIMENTAL
Intervention: MRA women with typical LPDFs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ARA women with atypical LPDFs
Number of subjects: 30
Study: 26465780

Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg orally, once daily for 28 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg on Day 28
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Number of subjects: 24
Study: 26466143

Group type: EXPERIMENTAL
Intervention: Molecular-barcode-based immune repertoire sequencing assay
Number of subjects: 12
Study: 26466328

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 μg)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 305
Study: 26466682

Group type: EXPERIMENTAL
Intervention: p-STAT6 and PU.1 expression in Th9 cells; NF-κB expression in eosinophils; serum IL-9 and IL-5 levels.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bronchial allergen challenge.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Eosinophil apoptosis.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation analysis in AA group.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation between MFI of NF-κB and eosinophil apoptosis.
Number of subjects: 19
Study: 26467105

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT-MPI)
Number of subjects: 391
Study: 26467455

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Number of subjects: 504

Group type: COMPARATOR
Intervention: DTC-negative BM
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Bisphosphonate application
Number of subjects: 504
Study: 26467555

Group type: EXPERIMENTAL
Intervention: Ubiquitin C-terminal hydrolase-L1 (UCH-L1) measured within 6 hours of injury
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein (GFAP) measured within 6 hours of injury
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: S100B measured within 6 hours of injury
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: All three biomarkers (GFAP, UCH-L1, S100B)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 251
Study: 26467644

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 6.5%
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: HbA1c threshold of 6.3%
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 5.6%
Number of subjects: 1128

Group type: COMPARATOR
Intervention: OGTT
Number of subjects: 1128
Study: 26468043

Group type: EXPERIMENTAL
Intervention: Serologically confirmed pertussis infection (anti-PT IgG titre ⩾62·5 IU/ml)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Longer duration of cough, paroxysms, breathlessness/chest pain
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Median total direct medical cost per pertussis episode
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: EQ-5D index score of cases
Number of subjects: 312
Study: 26468228

Group type: EXPERIMENTAL
Intervention: Blockade of PD-L1
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: T-cell immunity against stem-cell antigen SOX2
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Expression of PD-L1 on tumor and infiltrating T cells
Number of subjects: 305
Study: 26468991

Group type: EXPERIMENTAL
Intervention: Wearable, long-duration, low-intensity ultrasonic device applied for 4 hours a day, at least 5 times per week over 6 weeks.
Number of subjects: 25
Study: 26469381

Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 45
Study: 26471212

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DM/Q) 20/10 mg twice daily
Number of subjects: 134
Study: 26471772

Group type: EXPERIMENTAL
Intervention: Decreased femoral offset (FO) group (more than 5 mm reduction)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Restored femoral offset (FO) group (within 5 mm restoration)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Increased femoral offset (FO) group (more than 5 mm increment)
Number of subjects: 250

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Global FO reduction
Number of subjects: 250

Group type: COMPARATOR
Intervention: Incidence of residual hip pain and analgesics use
Number of subjects: 250
Study: 26471854

Group type: EXPERIMENTAL
Intervention: Quadriceps strength and quadriceps activation failure (QAF)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Interaction of strength by QAF
Number of subjects: 52
Study: 26471917

Group type: EXPERIMENTAL
Intervention: Acessa Guidance System
Number of subjects: 5
Study: 26472037

Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic treatment for tracheobronchitis
Number of subjects: 2960

Group type: COMPARATOR
Intervention: Inappropriate antibiotic treatment for tracheobronchitis
Number of subjects: 2960

Group type: COMPARATOR
Intervention: Ventilator-associated pneumonia
Number of subjects: 2960

Group type: COMPARATOR
Intervention: Tracheobronchitis
Number of subjects: 2960

Group type: COMPARATOR
Intervention: No ventilator-associated lower respiratory tract infections
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Tracheobronchitis and pneumonia
Number of subjects: 2960
Study: 26472401

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CRP and PCT
Number of subjects: 200
Study: 26472629

Group type: EXPERIMENTAL
Intervention: Participants with Huntington's disease mutation (1,007)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Companion ratings
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Controls (298)
Number of subjects: 1305
Study: 26472751

Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg twice daily continuously for 48 weeks plus rituximab 375 mg/m(2) weekly ×8
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Idelalisib plus rituximab
Number of subjects: 64
Study: 26473643

Group type: EXPERIMENTAL
Intervention: AZD9291 at doses of 20 to 80 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AZD9291
Number of subjects: 4
Study: 26473774

Group type: EXPERIMENTAL
Intervention: Fully endoscopic transsphenoidal surgery (performed by a less experienced surgeon)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Microscopic transsphenoidal surgery (performed by a very experienced surgeon)
Number of subjects: 135
Study: 26474010

Group type: EXPERIMENTAL
Intervention: Extended release quetiapine (quetiapine XR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0